Last week's profit announcement from Nephros, Inc. (NASDAQ:NEPH) was underwhelming for investors, despite headline numbers being robust. We did some digging and found some worrying underlying problems.
As finance nerds would already know, the accrual ratio from cashflow is a key measure for assessing how well a company's free cash flow (FCF) matches its profit. To get the accrual ratio we first subtract FCF from profit for a period, and then divide that number by the average operating assets for the period. The ratio shows us how much a company's profit exceeds its FCF.
As a result, a negative accrual ratio is a positive for the company, and a positive accrual ratio is a negative. While it's not a problem to have a positive accrual ratio, indicating a certain level of non-cash profits, a high accrual ratio is arguably a bad thing, because it indicates paper profits are not matched by cash flow. To quote a 2014 paper by Lewellen and Resutek, "firms with higher accruals tend to be less profitable in the future".
Nephros has an accrual ratio of 0.44 for the year to September 2026. Statistically speaking, that's a real negative for future earnings. To wit, the company did not generate one whit of free cashflow in that time. Even though it reported a profit of US$1.91m, a look at free cash flow indicates it actually burnt through US$910k in the last year. We saw that FCF was US$2.7m a year ago though, so Nephros has at least been able to generate positive FCF in the past. The good news for shareholders is that Nephros' accrual ratio was much better last year, so this year's poor reading might simply be a case of a short term mismatch between profit and FCF. As a result, some shareholders may be looking for stronger cash conversion in the current year.
That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.
As we have made quite clear, we're a bit worried that Nephros didn't back up the last year's profit with free cashflow. As a result, we think it may well be the case that Nephros' underlying earnings power is lower than its statutory profit. The good news is that, its earnings per share increased by 27% in the last year. At the end of the day, it's essential to consider more than just the factors above, if you want to understand the company properly. In light of this, if you'd like to do more analysis on the company, it's vital to be informed of the risks involved. For example, we've found that Nephros has 3 warning signs (1 makes us a bit uncomfortable!) that deserve your attention before going any further with your analysis.
Today we've zoomed in on a single data point to better understand the nature of Nephros' profit. But there are plenty of other ways to inform your opinion of a company. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks with significant insider holdings to be useful.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.